STELARA® dosing and administration for adult patients with moderately to severely active UC
STELARA® OFFERS UNIQUELY DESIGNED DOSING IN UC1
Single IV induction dose followed by subQ maintenance treatments every 8 weeks
A Single IV Induction
A Single IV Induction
Single IV induction dose administered over at least 1 hour
| Body weight* of patient at the time of dosing | Dose |
Number of 130 mg/26 mL (5 mg/mL) STELARA® vials |
| 55 kg or less | 260 mg | 2 |
| more than 55 kg to 85 kg | 390 mg | 3 |
| more than 85 kg | 520 mg | 4 |
SubQ Maintenance†
90-mg dose every 8 weeks after induction dose
6 subQ maintenance doses during Year 1
For optimal outcome, STELARA® should be dosed and administered as described in the Prescribing Information
- Please refer to the Dosage and Administration section of the full Prescribing Information for complete information on how to prepare and administer STELARA®
- STELARA® is intended for use under the guidance and supervision of a physician with patients who will be closely monitored and have regular follow-up
- Patients may self-inject with STELARA® after physician approval and proper training
- Patients should be instructed to follow the direction provided in the Medication Guide
View dosing and administration of STELARA® in CD
CD=Crohn's disease; IV=intravenous; subQ=subcutaneous; UC=ulcerative colitis.
*Approximately 2.2 pounds per kilogram.
†Induction dose: A single IV infusion using a weight-based dosage regimen: STELARA® 260 mg (weight ≤55 kg), STELARA® 390 mg (weight >55 kg to 85 kg), STELARA® 520 mg (weight >85 kg). Maintenance dose: A subQ 90-mg dose administered every 8 weeks after the induction dose.
NUMBER OF DOSES AMONG SELECT UC+CD BIOLOGICS
Total doses in the first 52 weeks for adult patients
STELARA®1*
7
Single IV weight-based induction dose administered over at least 1 hour; 6 subQ injection maintenance doses of 90 mg (1 every 8 weeks after induction dose).
Entyvio®(vedolizumab)2†
8
300-mg IV infusion, administered over a period of about 30 minutes, at 0, 2, and 6 weeks, and then every 8 weeks thereafter.
Humira® (adalimumab)3‡
27
Three starter injections of 80 mg in 2 doses (on Day 1 and Day 15); 25 subQ injection maintenance doses of 40 mg (1 every other week thereafter).
KEY:
IV infusion
subQ injection
pre-filled syringes
subQ injection pen
This presentation is not intended to compare the relative safety or efficacy of these treatments. Please refer to each product’s full Prescribing Information.
Indicated trademarks are registered trademarks of their respective owners.
CD=Crohn's disease; IV=intravenous; subQ=subcutaneous; TNF=tumor necrosis factor; UC=ulcerative colitis.
*Induction dose: A single IV infusion using a weight-based dosage regimen: STELARA® 260 mg (weight ≤55 kg), STELARA® 390 mg (weight >55 kg to 85 kg), STELARA® 520 mg (weight >85 kg). Maintenance dose: A subQ 90-mg dose administered every 8 weeks after the induction dose.
†Based on 300 mg administered by IV.
‡The recommended dosing for Humira® is 160 mg initially on Day 1 (given in 1 day or split over 2 consecutive days), followed by 80 mg 2 weeks later (Day 15). Two weeks later (Day 29), begin a maintenance dose of 40 mg every other week.
WRITE 2 PRESCRIPTIONS FOR STELARA®1
One for the single IV induction dose* and 1 for subQ maintenance treatment
To learn more about prescribing STELARA®, visit the support page
IV=intravenous; subQ=subcutaneous.
*The single IV infusion dose and number of vials are determined using a weight-based dosage regimen: STELARA® 260 mg (weight ≤55 kg), STELARA® 390 mg (weight >55 kg to 85 kg), or STELARA® 520 mg (weight >85 kg). Please refer to the full Prescribing Information for the complete dosing information.
References: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Entyvio® [Prescribing Information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc. 3. Humira® [Prescribing Information]. North Chicago, IL: AbbVie Inc.
